Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 12, 2005

View Archived Issues

PTC-124 begins phase II study for cystic fibrosis with FDA funding

Study to compare Xyotax and paclitaxel in women with advanced NSCLC

Exelixis and Bristol-Myers Squibb collaborate on LXR-targeting therapies

First milestone in Evotec and Takeda's Alzheimer's collaboration

Cephalon to acquire Zeneus Holdings

CA4P to be studied in combination with Avastin

BioDiem to study BDM-E in patients with diabetic macula edema

Inamed receives irrevocable offer and merger agreement from Allergan

First clinical trial of L-annamycin in relapsed and refractory ALL

PRTX-100 tested for first time in humans

Novelos to advance NOV-002 into pivotal phase III study for advanced NSCLC

Borean Pharma establishes proof-of-concept for TNF-alpha antagonist

New ROCK inhibitor displays antiangiogenic and antitumor effects

PK and tolerability profile of darunavir/low-dose ritonavir in humans

MK-0518: An effective short-term therapy in HIV-1 patients

Breast cancer responses not increased with tipifarnib-letrozole combination

ZK-EPO active in human breast cancer models

Scutellaria barbata extract (BZL-101) evaluated in phase I breast cancer trial

TAS-108 active, with acceptable toxicity, in postmenopausal breast cancer patients

Targeting Mcl-1 for leukemia

Xyrem launched in Germany for cataplexy in adult with narcolepsy

NDA filed for NRP-104 in ADHD

New analgesic agents reported in patent literature

Companies patent novel agents for gastrointestinal disorders

New agents reported with potential in treatment of Parkinson's disease and other disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...